🎗️🔬 INiBICA participates in the 2nd Translational Conference on Precision Oncology held in Seville 🔬🎗️
👨🔬👩🔬 On February 6 and 7, the Second Translational Conference on Precision Oncology, “Through Signaling Pathways,” was held in Seville, bringing together more than 50 experts in oncology and molecular biology to discuss advances in precision medicine for cancer. 💬 The event, coordinated by Dr. Javier Salvador, Dr. Reyes Bernabé, and Dr. Michele Biscuola, included roundtable discussions and scientific presentations. Participants addressed the role of genetics and HER receptors in various types of cancer, highlighting their inhibition as a therapeutic strategy. Advances in immunotherapy for melanoma, bladder cancer, breast cancer, and small-cell lung cancer were also discussed. 🔬 Another key topic was the development of targeted therapies, with an emphasis on the RAS and PI3K-AKT-mTOR pathways, which enable personalized treatments for brain tumors and cholangiocarcinoma. In addition, the identification of patients with RET and ALK gene fusions was analyzed; these patients could benefit from innovative therapies without resorting to conventional chemotherapy or immunotherapy. 🧫 The importance of DNA repair in breast and ovarian cancer was highlighted, as it influences treatment selection. To conclude, a roundtable discussion addressed quality in precision medicine and the role of NGS reports in clinical decision-making. 🤝 This meeting reaffirms the medical community’s commitment to advancing toward more personalized and effective treatments for cancer patients. 🔗 More information: Europa Press || Virgen del Rocío University Hospital || Instagram









